Cour Pharmaceuticals Development Co. Inc. has obtained IND clearance from the FDA for CNP-103, a nanoparticle in development to address the underlying autoimmunity of type 1 diabetes. A first-in-human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback